Niki BioSolutions, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount
Niki BioSolutions, Inc. (NIKI) had Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount of $4.08 million as of 2025-09-30, per its 6-K filed 2026-01-22.
Financial Statements › Notes › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount · last filed 2026-01-22
- 2025-09-30: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount $4.08M.
- 2024-12-31: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount $4.08M; Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount as first filed $1.52M.
- 2023-12-31: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount $520.82K.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount as first filed |
|---|---|---|
| 2025-09-30 | $4.08M 6-K · filed 2026-01-22 | |
| 2024-12-31 | $4.08M 6-K · filed 2026-01-22 | $1.52M 6-K · filed 2025-10-08 |
| 2023-12-31 | $520.82K 6-K · filed 2025-10-08 |